Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
McKinsey
Moodys
AstraZeneca
Healthtrust

Generated: August 19, 2019

DrugPatentWatch Database Preview

Litigation Details for ORTHO-MCNEIL PHARMACEUTICAL, INC. v. MYLAN LABORATORIES INC. (D.N.J. )

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in ORTHO-MCNEIL PHARMACEUTICAL, INC. v. MYLAN LABORATORIES INC.
The small molecule drug covered by the patent cited in this case is   Try a Free Trial .

Details for ORTHO-MCNEIL PHARMACEUTICAL, INC. v. MYLAN LABORATORIES INC. (D.N.J. )

Date Filed Document No. Description Snippet Link To Document
2006-05-30 134 United States Patent and Trademark Office (“PTO”) issued United States patent number 4,513,006 (the “‘006…expiration of the ‘006 patent. (Id. at ¶ 14.) In its ANDA, Mylan claims that the ‘006 patent is invalid and…David Levy, Esq., the patent attorney involved in prosecuting the ‘006 patent. 2 …to issue a patent on claims that did not meet the statutory requirements for patentability.” (Am. Answer… references were before the patent examiner at the time the ‘006 patent was granted. Indeed, they were External link to document
2006-10-05 159 United States Patent and Trademark Office (“PTO”) issued United States patent number 4,513,006 (the “’006…pharmaceutically-acceptable carrier.” (’006 Patent, col. 8, ll: 6-9.) Mylan argues that the ’006 patent is invalid under § …the ‘06 patent. Mylan has therefore not pointed to any evidence that the ’006 patent is invalid… BACKGROUND This is a patent infringement case brought under the Hatch-Waxman…006 patent”) to McNeilab, Inc. as assignee of inventors Bruce E. Maryanoff and Joseph F. Gardocki. External link to document
2006-10-23 169 United States Patent and Trademark Office (“PTO”) issued United States Patent No. 4,513,006 (the “’006…expiration of the ’006 patent. (Id. at ¶ 14.) In its ANDA, Mylan claimed that the ’006 patent is invalid and…affirmative defenses to patent infringement, Mylan has asserted that the ’006 patent is invalid under …Defendants likely infringe the patent, and (2) the claims of the patent will likely withstand Defendants… To patent an invention, the subject matter must be non-obvious: A patent may not be External link to document
2007-02-05 198 United States Patent and Trademark Office (“PTO”) issued United States patent number 4,513,006 (the “’006…expiration of the ’006 patent. (Id. at ¶ 14.) In its ANDA, Mylan claimed that the ’006 patent is invalid and… Mylan’s patent invalidity defenses have been resolved but one: Mylan’s defense of patent invalidity…5 of 15 PageID: 7622 II. Patent validity “A patent shall be presumed valid.” 35 U.S.… To patent an invention, the subject matter must be non-obvious: A patent may not be External link to document
2007-03-20 206 concerns infringement of U.S. Patent No. 4,513,006 (the “’006 patent”). With this motion, Ortho seeks…factor, this Court has determined that Ortho’s patent is valid and that Mylan has infringed it; Ortho… earlier than the date of the expiration of the patent which has been infringed . . . 35 U.S.C. § 271…earlier than the expiration date of the infringed patent. . . In the case where an ANDA had been approved… 2:04-cv-01689-SRC-CCC Patent District Court, D. New Jersey External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
UBS
AstraZeneca
Fuji
Citi
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.